{"id":55878,"date":"2026-01-30T12:34:13","date_gmt":"2026-01-30T04:34:13","guid":{"rendered":"https:\/\/flcube.com\/?p=55878"},"modified":"2026-01-30T12:34:14","modified_gmt":"2026-01-30T04:34:14","slug":"genhouse-bio-files-hong-kong-ipo-with-phase-ii-shp2-inhibitor-gh21","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55878","title":{"rendered":"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Suzhou Genhouse Bio Co., Ltd.<\/strong> submitted its initial public offering (IPO) filing to the <strong>Hong Kong Stock Exchange (HKSE)<\/strong> this week. Founded in 2014, the biopharmaceutical company has built a differentiated pipeline focused on the <strong>RAS signaling pathway<\/strong> and <strong>synthetic lethality<\/strong> mechanisms, with seven self\u2011developed oral small\u2011molecule targeted therapies, four of which have entered clinical development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-ipo-details\">Company Profile &amp; IPO Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Suzhou Genhouse Bio Co., Ltd.<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2014<\/td><\/tr><tr><td><strong>IPO Venue<\/strong><\/td><td>Hong Kong Stock Exchange (HKSE)<\/td><\/tr><tr><td><strong>Focus Areas<\/strong><\/td><td>RAS signaling pathway, synthetic lethality<\/td><\/tr><tr><td><strong>Pipeline Size<\/strong><\/td><td>7 self\u2011developed oral small\u2011molecule targeted therapies<\/td><\/tr><tr><td><strong>Clinical Stage Assets<\/strong><\/td><td>4 candidates<\/td><\/tr><tr><td><strong>Core Product<\/strong><\/td><td>GH21 (allosteric SHP2 inhibitor)<\/td><\/tr><tr><td><strong>GH21 Stage<\/strong><\/td><td>Phase\u202fII clinical trials for solid tumors<\/td><\/tr><tr><td><strong>Market Position<\/strong><\/td><td>Potential best\u2011in\u2011class SHP2 inhibitor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-overview-amp-technology-platform\">Pipeline Overview &amp; Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RAS Pathway Focus:<\/strong> Targets one of oncology\u2019s most high\u2011value yet historically undruggable pathways<\/li>\n\n\n\n<li><strong>Synthetic Lethality:<\/strong> Exploits cancer\u2011specific vulnerabilities for enhanced selectivity and safety<\/li>\n\n\n\n<li><strong>Oral Small\u2011Molecule Advantage:<\/strong> All candidates are orally bioavailable, offering dosing convenience versus injectable biologics<\/li>\n\n\n\n<li><strong>Clinical Stage Assets:<\/strong> Four programs advancing through Phase\u202fI\/II, providing near\u2011term catalysts beyond GH21<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-product-gh21-shp2-inhibitor\">Core Product: GH21 SHP2 Inhibitor<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Allosteric SHP2 inhibitor<\/strong> targeting the protein tyrosine phosphatase that acts as a critical node downstream of RAS signaling<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Potential <strong>best\u2011in\u2011class<\/strong> profile based on preclinical potency and selectivity data<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Phase\u202fII trials in <strong>solid tumors<\/strong>, including potential combination strategies with KRAS G12C inhibitors<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> SHP2 represents a <strong>validated resistance mechanism<\/strong> to targeted therapies; no approved SHP2 inhibitors exist<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-positioning\">Market Opportunity &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SHP2 Inhibitor Market:<\/strong> Global market projected to exceed <strong>$5\u202fbillion<\/strong> :by 2030 if clinically validated, driven by RAS pathway drug combinations<\/li>\n\n\n\n<li><strong>RAS Pathway Landscape:<\/strong> Complements <strong>Amgen\u2019s Lumakras<\/strong> and <strong>Mirati\u2019s Krazati<\/strong>; GH21 could become cornerstone of next\u2011generation combo regimens<\/li>\n\n\n\n<li><strong>IPO Valuation:<\/strong> Analysts estimate <strong>$300\u2013500\u202fmillion<\/strong> pre\u2011money valuation based on pipeline novelty and clinical progress<\/li>\n\n\n\n<li><strong>Use of Proceeds:<\/strong> Funds expected to advance GH21 through Phase\u202fII, expand synthetic lethality pipeline, and build commercial manufacturing capabilities<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> Proprietary AI\u2011driven drug design platform enables rapid iteration on novel scaffolds, creating high barriers to entry<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Genhouse Bio\u2019s IPO timeline, clinical development, and market potential. Actual results may differ due to market conditions, clinical trial outcomes, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55880,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4529,72],"class_list":["post-55878","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-genhouse-bio","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE) this week. Founded in 2014, the biopharmaceutical company has built a differentiated pipeline focused on the RAS signaling pathway and synthetic lethality mechanisms, with seven self\u2011developed oral small\u2011molecule targeted therapies, four of which have entered clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55878\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21\" \/>\n<meta property=\"og:description\" content=\"Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE) this week. Founded in 2014, the biopharmaceutical company has built a differentiated pipeline focused on the RAS signaling pathway and synthetic lethality mechanisms, with seven self\u2011developed oral small\u2011molecule targeted therapies, four of which have entered clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55878\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T04:34:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T04:34:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3004.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21\",\"datePublished\":\"2026-01-30T04:34:13+00:00\",\"dateModified\":\"2026-01-30T04:34:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878\"},\"wordCount\":401,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3004.webp\",\"keywords\":[\"Genhouse Bio\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55878#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55878\",\"name\":\"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3004.webp\",\"datePublished\":\"2026-01-30T04:34:13+00:00\",\"dateModified\":\"2026-01-30T04:34:14+00:00\",\"description\":\"Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE) this week. Founded in 2014, the biopharmaceutical company has built a differentiated pipeline focused on the RAS signaling pathway and synthetic lethality mechanisms, with seven self\u2011developed oral small\u2011molecule targeted therapies, four of which have entered clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55878\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3004.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3004.webp\",\"width\":1080,\"height\":608,\"caption\":\"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55878#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21 - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE) this week. Founded in 2014, the biopharmaceutical company has built a differentiated pipeline focused on the RAS signaling pathway and synthetic lethality mechanisms, with seven self\u2011developed oral small\u2011molecule targeted therapies, four of which have entered clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55878","og_locale":"en_US","og_type":"article","og_title":"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21","og_description":"Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE) this week. Founded in 2014, the biopharmaceutical company has built a differentiated pipeline focused on the RAS signaling pathway and synthetic lethality mechanisms, with seven self\u2011developed oral small\u2011molecule targeted therapies, four of which have entered clinical development.","og_url":"https:\/\/flcube.com\/?p=55878","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-30T04:34:13+00:00","article_modified_time":"2026-01-30T04:34:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3004.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55878#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55878"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21","datePublished":"2026-01-30T04:34:13+00:00","dateModified":"2026-01-30T04:34:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55878"},"wordCount":401,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55878#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3004.webp","keywords":["Genhouse Bio","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55878#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55878","url":"https:\/\/flcube.com\/?p=55878","name":"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55878#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55878#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3004.webp","datePublished":"2026-01-30T04:34:13+00:00","dateModified":"2026-01-30T04:34:14+00:00","description":"Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE) this week. Founded in 2014, the biopharmaceutical company has built a differentiated pipeline focused on the RAS signaling pathway and synthetic lethality mechanisms, with seven self\u2011developed oral small\u2011molecule targeted therapies, four of which have entered clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55878#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55878"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55878#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3004.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3004.webp","width":1080,"height":608,"caption":"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55878#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3004.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55878"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55878\/revisions"}],"predecessor-version":[{"id":55881,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55878\/revisions\/55881"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55880"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}